Trial Profile
Evaluation of the Tolerance and Acceptability of Rasagiline in the Treatment of Early-stage Parkinson's Disease
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 12 Aug 2015
Price :
$35
*
At a glance
- Drugs Rasagiline (Primary) ; Pramipexole
- Indications Parkinson's disease
- Focus Adverse reactions
- Acronyms ACTOR
- 21 Jun 2012 Results presented at the 16th International Congress of Parkinson's Disease and Movement Disorders.
- 25 May 2012 Actual patient number is 112 as reported by ClinicalTrials.gov.
- 25 May 2012 Actual end date (1 Mar 2010) added as reported by ClinicalTrials.gov.